Article

Ophthalmology community mourns loss of Judah Folkman, MD

The ophthalmology community mourns the loss of Judah Folkman, MD, innovator and researcher, who died Monday in Denver.

Denver-The ophthalmology community mourns the loss of Judah Folkman, MD, innovator and researcher, who died Monday in Denver. Dr. Folkman, a professor at Harvard and director of the vascular biology program at Children's Hospital, Boston, sparked major advances in the treatment of eye diseases and other illnesses that involve excessive or abnormal angiogenesis, or blood vessel development.

"Dr. Folkman's death is a loss to ophthalmology and to all of medicine," said H. Dunbar Hoskins Jr., MD, executive vice president for the American Academy of Ophthalmology (AAO). "Because of his groundbreaking work, we have seen remarkable advances in helping patients with age-related macular degeneration (AMD) save their vision and even regain some of their eyesight."

Dr. Folkman was the keynote speaker this past fall at the annual meeting of the AAO in New Orleans. He expressed that ophthalmology was present at the beginning of his research into angiogenesis.

Along with his research group, Dr. Folkman identified the first angiogenesis inhibitors in 1985, after enduring fellow scientists' scorn for their approach for 20 years. Today, at least 40 compounds that affect angiogenesis are being tested in humans to combat a range of cancers, heart disease, and eye diseases including AMD, retinopathy of prematurity, and diabetes-related disorders.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.